Table 1.
Clinicopathological features in the prospective cohort, in all patients (first column) or stratified according to “Low” and “High” biomarker score in the urine or plasma.
| Factors | All |
Stratified upon plasma score |
Stratified upon urine score |
||
|---|---|---|---|---|---|
| N = 31 | Low (N = 15) | High (N = 15) | Low (N = 14) | High (N = 15) | |
| Age | 65 (58–77) | 67 (61–80) | 63 (56–74) | 65 (56–74) | 65 (58–77) |
| Gender | |||||
| Female | 9 | 7 | 2 | 6 | 3 |
| Male | 22 | 8 | 13 | 8 | 12 |
| BMI | 23.6 (22.5–26.7) | 23.2 (23.1–24.5) | 26.1 (22.3–28.1) | 23.0 (20.3–23.9) | 26.1 (23.3–28.0) |
| Smoking habits | |||||
| Never smoker | 18 | 9 | 8 | 8 | 9 |
| Ex-smoker | 8 | 1 | 7 | 1 | 6 |
| Presence of metastasis | |||||
| Yes | 23 | 7 | 15 | 6 | 15 |
| No | 8 | 8 | 0 | 8 | 0 |
| Tumor stage | |||||
| T1/T1a/T1b | 9 | 7 | 2 | 7 | 2 |
| T2/T2a | 10 | 5 | 5 | 3 | 6 |
| T3> | 9 | 2 | 6 | 3 | 5 |
| N0 | 16 | 9 | 7 | 8 | 8 |
| N1 | 1 | 0 | 1 | 0 | 1 |
| NX | 14 | 6 | 6 | 6 | 6 |
| Fuhrman tumor grade | |||||
| Grade 2 | 14 | 7 | 6 | 5 | 9 |
| Grade 3 | 9 | 4 | 5 | 3 | 5 |
| Grade 4 | 4 | 2 | 2 | 4 | 0 |
| ECOG performance status | |||||
| 0 | 18 | 10 | 8 | 10 | 7 |
| 1 | 13 | 5 | 7 | 4 | 8 |
| Heng classification | |||||
| Good | 15 | 10 | 5 | 8 | 6 |
| Intermediate | 15 | 4 | 10 | 5 | 9 |
| Neutrophile-to-lymphocite | |||||
| <3 | 24 | 10 | 13 | 10 | 13 |
| ≥3 | 5 | 3 | 2 | 2 | 2 |
| Biomarker score | – | 0.25 (0.14–0.67) | 1.37 (1.10–1.74) | 0.75 (0.54–1.10) | 1.49 (1.24–1.87) |
Distributions are summarized as median and interquartile ranges in brackets.